ED Huguenel, D Cohn, DP Dockum, JM Greve, MA Fournel, L Hammond, R Irwin, J Mahoney, A McClelland, E Muchmore, AC Ohlin and P Scuderi
Bayer Research Center West Haven, Connecticut 06516-4175, USA.

Intercellular adhesion molecule-1 (ICAM-1) is the cell surface receptor for the major class of human rhinoviruses, and tICAM453, a truncated, soluble form of ICAM-1, has been shown previously to be a potent in vitro inhibitor of rhinovirus. In this report, we have investigated the in vivo efficacy of tICAM453 for the prophylaxis of rhinovirus serotype 16 infection in the chimpanzee. Because chimpanzees do not show clinical symptoms of infection after rhinovirus challenge, infection was followed by measuring antirhinovirus serum antibody responses and detection of virus shedding. By both of these measures, intranasal application of tICAM453 was efficacious in preventing rhinovirus infection in chimpanzees subsequently challenged with infectious doses of virus. These results suggest that the use of soluble rhinovirus receptor to inhibit virus binding to host cells should be feasible in humans.

This article has been cited by other articles:

				K. Liu, R. C. Gualano, M. L. Hibbs, G. P. Anderson, and S. Bozinovski Epidermal Growth Factor Receptor Signaling to Erk1/2 and STATs Control the Intensity of the Epithelial Inflammatory Responses to Rhinovirus Infection J. Biol. Chem., April 11, 2008; 283(15): 9977 - 9985. [Abstract] [Full Text] [PDF]

				S. C. Whiteman, A. Bianco, R. A. Knight, and M. A. Spiteri Human Rhinovirus Selectively Modulates Membranous and Soluble Forms of Its Intercellular Adhesion Molecule-1 (ICAM-1) Receptor to Promote Epithelial Cell Infectivity J. Biol. Chem., March 28, 2003; 278(14): 11954 - 11961. [Abstract] [Full Text] [PDF]

				P. J. Lindsberg, J. Launes, L. Tian, H. Valimaa, V. Subramanian, J. Siren, L. Hokkanen, T. Hyypia, O. Carpen, and C. G. Gahmberg Release of soluble ICAM-5, a neuronal adhesion molecule, in acute encephalitis Neurology, February 12, 2002; 58(3): 446 - 451. [Abstract] [Full Text] [PDF]

				T. Suzuki, M. Yanai, M. Yamaya, T. Satoh-Nakagawa, K. Sekizawa, S. Ishida, and H. Sasaki Erythromycin and Common Cold in COPD Chest, September 1, 2001; 120(3): 730 - 733. [Abstract] [Full Text] [PDF]

				N. J. C. Snell New treatments for viral respiratory tract infections--opportunities and problems J. Antimicrob. Chemother., March 1, 2001; 47(3): 251 - 259. [Full Text] [PDF]

				R. Weltzin and T. P. Monath Intranasal Antibody Prophylaxis for Protection against Viral Disease Clin. Microbiol. Rev., July 1, 1999; 12(3): 383 - 393. [Abstract] [Full Text] [PDF]

				R. B. Turner, M. T. Wecker, G. Pohl, T. J. Witek, E. McNally, R. St. George, B. Winther, and F. G. Hayden Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection: A Randomized Clinical Trial JAMA, May 19, 1999; 281(19): 1797 - 1804. [Abstract] [Full Text] [PDF]

				J. E. Gern and W. W. Busse Association of Rhinovirus Infections with Asthma Clin. Microbiol. Rev., January 1, 1999; 12(1): 9 - 18. [Abstract] [Full Text] [PDF]

				G. FOLKERTS, W. W. BUSSE, F. P. NIJKAMP, R. SORKNESS, and J. E. GERN Virus-induced Airway Hyperresponsiveness and Asthma Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1708 - 1720. [Full Text] [PDF]